BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis

U Heinicke, T Haydn, S Kehr, M Vogler, S Fulda - Oncogene, 2018 - nature.com
BH3 mimetics are emerging novel anticancer therapeutics that potently and specifically
inhibit antiapoptotic BCL-2 proteins and thereby induce cell death in many cancer entities …
被引用次数：36 相关文章

BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis.

U Heinicke, T Haydn, S Kehr, M Vogler, S Fulda - Oncogene, 2018 - europepmc.org
BH3 mimetics are emerging novel anticancer therapeutics that potently and specifically
inhibit antiapoptotic BCL-2 proteins and thereby induce cell death in many cancer entities …

BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis

U Heinicke, T Haydn, S Kehr, M Vogler… - …, 2018 - pubmed.ncbi.nlm.nih.gov
BH3 mimetics are emerging novel anticancer therapeutics that potently and specifically
inhibit antiapoptotic BCL-2 proteins and thereby induce cell death in many cancer entities …

BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis

U Heinicke, T Haydn, S Kehr, M Vogler, S Fulda - Oncogene, 2018 - go.gale.com
BH3 mimetics are emerging novel anticancer therapeutics that potently and specifically
inhibit antiapoptotic BCL-2 proteins and thereby induce cell death in many cancer entities …